HCA
BLFS icon

Horan Capital Advisors’s BioLife Solutions BLFS Stock Holding History

Horan Capital Advisors’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,022
Closed -$297K – 91
2021
Q3 		$297K Buy
+7,022
New +$338K 0.13% 80

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.36B AUM 17.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Horan Capital Advisors's BLFS Position: Q4 2021 in Review

Horan Capital Advisors sold out of BioLife Solutions (BLFS) in Q4 2021, closing a stake of 7,022 shares — an estimated $297K sold.

Horan Capital Advisors first reported a position in BLFS in Q3 2021 and held it in 1 quarter. The position peaked at $297K in Q3 2021. 169 funds tracked by Wall St. Rank hold BLFS as of Q4 2021.

  • Horan Capital Advisors reported no remaining BioLife Solutions position as of Q4 2021 after selling out during the quarter.
  • Horan Capital Advisors sold 7,022 BioLife Solutions shares in Q4 2021, an estimated $297K.
  • Horan Capital Advisors first reported a position in BioLife Solutions in Q3 2021 and held it in 1 quarter.
  • Horan Capital Advisors's BioLife Solutions position peaked at $297K in Q3 2021.
  • 169 funds tracked by Wall St. Rank held BioLife Solutions as of Q4 2021.

Based on Horan Capital Advisors's 13F filing for Q4 2021, filed 1 Feb 2022.